IART Integra Lifesciences Holdings Corp

Price (delayed)

$55.83

Market cap

$4.64B

P/E Ratio

30.18

Dividend/share

N/A

EPS

$1.85

Enterprise value

$5.88B

Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra ...

Highlights
The stock's price to earnings (P/E) is 51% less than its 5-year quarterly average of 60.7 and 4.4% less than its last 4 quarters average of 30.8
The gross profit is up by 14% year-on-year and by 2.1% since the previous quarter
IART's quick ratio is up by 33% YoY but it is down by 7% from the previous quarter
The equity has increased by 6% year-on-year but it has declined by 4.1% since the previous quarter
Integra Lifesciences Holdings's net income has decreased by 8% YoY and by 7% from the previous quarter
IART's EPS is down by 8% year-on-year and by 8% since the previous quarter

Key stats

What are the main financial stats of IART
Market
Shares outstanding
83.14M
Market cap
$4.64B
Enterprise value
$5.88B
Valuations
Price to earnings (P/E)
30.18
Price to book (P/B)
2.88
Price to sales (P/S)
2.99
EV/EBIT
24.95
EV/EBITDA
16.41
EV/Sales
3.77
Earnings
Revenue
$1.56B
EBIT
$235.84M
EBITDA
$358.48M
Free cash flow
$237.02M
Per share
EPS
$1.85
Free cash flow per share
$2.83
Book value per share
$19.4
Revenue per share
$18.64
TBVPS
$18.43
Balance sheet
Total assets
$3.67B
Total liabilities
$2.06B
Debt
$1.65B
Equity
$1.62B
Working capital
$750.22M
Liquidity
Debt to equity
1.02
Current ratio
3.38
Quick ratio
2.03
Net debt/EBITDA
3.46
Margins
EBITDA margin
23%
Gross margin
61.9%
Net margin
10%
Operating margin
13.6%
Efficiency
Return on assets
4.2%
Return on equity
9.6%
Return on invested capital
9.6%
Return on capital employed
7%
Return on sales
15.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IART stock price

How has the Integra Lifesciences Holdings stock price performed over time
Intraday
2.52%
1 week
2.97%
1 month
-10.17%
1 year
-18.52%
YTD
-16.66%
QTD
-13.12%

Financial performance

How have Integra Lifesciences Holdings's revenue and profit performed over time
Revenue
$1.56B
Gross profit
$964.46M
Operating income
$212.68M
Net income
$156.58M
Gross margin
61.9%
Net margin
10%
The operating income has grown by 37% year-on-year and by 8% since the previous quarter
IART's operating margin is up by 21% year-on-year and by 6% since the previous quarter
The net margin has declined by 19% year-on-year and by 9% since the previous quarter
The gross profit is up by 14% year-on-year and by 2.1% since the previous quarter

Growth

What is Integra Lifesciences Holdings's growth rate over time

Valuation

What is Integra Lifesciences Holdings stock price valuation
P/E
30.18
P/B
2.88
P/S
2.99
EV/EBIT
24.95
EV/EBITDA
16.41
EV/Sales
3.77
The stock's price to earnings (P/E) is 51% less than its 5-year quarterly average of 60.7 and 4.4% less than its last 4 quarters average of 30.8
IART's EPS is down by 8% year-on-year and by 8% since the previous quarter
The P/B is 22% lower than the 5-year quarterly average of 3.6 and 20% lower than the last 4 quarters average of 3.5
The equity has increased by 6% year-on-year but it has declined by 4.1% since the previous quarter
The price to sales (P/S) is 21% less than the last 4 quarters average of 3.7 and 14% less than the 5-year quarterly average of 3.4
The revenue is up by 13% year-on-year

Efficiency

How efficient is Integra Lifesciences Holdings business performance
Integra Lifesciences Holdings's return on equity has decreased by 18% YoY and by 9% QoQ
IART's ROA is down by 13% YoY and by 7% QoQ
IART's return on invested capital is up by 12% year-on-year but it is down by 11% since the previous quarter
IART's return on sales is down by 12% since the previous quarter and by 3.8% year-on-year

Dividends

What is IART's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IART.

Financial health

How did Integra Lifesciences Holdings financials performed over time
The company's total assets is 79% higher than its total liabilities
The current ratio has grown by 34% year-on-year
IART's quick ratio is up by 33% YoY but it is down by 7% from the previous quarter
The debt is 2.1% greater than the equity
Integra Lifesciences Holdings's debt to equity has decreased by 11% YoY but it has increased by 4.1% QoQ
The debt has declined by 6% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.